Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer

Chantal C H J Kuijpers, Cathy B. Moelans, Henk Jan Van Slooten, Anja Horstman, John W J Hinrichs, Shaimaa Al-Janabi, Paul J. Van Diest, Mehdi Jiwa

Research output: Contribution to journalArticle

Abstract

Background: HER-2 is a prognostic and predictive marker, but as yet no technique is perfectly able to identify patients likely to benefit from HER-2 targeted therapies. We aimed to prospectively assess the added value of first-line co-testing by IHC, and multiplex ligation-dependent probe amplification (MLPA) and chromogenic in situ hybridization (CISH). Methods: As local validation, HER-2 MLPA and CISH were compared in 99 breast cancers. Next, we reviewed 937 invasive breast cancers, from 4 Dutch pathology laboratories, that were prospectively assessed for HER-2 by IHC and MLPA (and CISH in selected cases). Results: The validation study demonstrated 100% concordance between CISH and MLPA, if both methods were assessable and conclusive (81.8% of cases). Significant variation regarding percentages IHC 0/1+ and 2+ cases was observed between the laboratories (p

Original languageEnglish (US)
Article numbere82018
JournalPLoS One
Volume8
Issue number12
DOIs
StatePublished - Dec 4 2013
Externally publishedYes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer'. Together they form a unique fingerprint.

Cite this